Welcome to our dedicated page for Abpro Holdings SEC filings (Ticker: ABP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Abpro Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Abpro Holdings's regulatory disclosures and financial reporting.
Abpro Holdings, Inc. reports that it has failed to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share by the September 29, 2025 deadline. On September 30, 2025, Nasdaq notified the company that its common stock is subject to delisting.
Unless Abpro appeals by October 7, 2025, its common stock would be scheduled for delisting at the opening of business on October 9, 2025. The company plans to request a hearing before a Nasdaq appeal panel, which will temporarily keep its securities trading while the panel reviews its plans to regain compliance.
Abpro cautions that there is no assurance the panel will grant continued listing or that it will meet all Nasdaq requirements within any extension period that might be provided.
Abpro Holdings, Inc. disclosed that its Chief Medical Officer, Dr. Robert J. Markelewicz, Jr., M.D., M.M.Sc., has been furloughed and will be leaving the company. Effective September 30, 2025, the company placed him on furlough through November 30, 2025, during which he will not perform any duties or responsibilities associated with his role. The filing states that his employment will be terminated effective November 30, 2025, signaling a planned transition away from this key executive position.